ReCode Therapeutics is a U.S. developer of precision therapies for lung diseases, working to correct nonsense mutations that account for one-third of all genetic diseases, including approximately 10% of cystic fibrosis. It combines selected tRNAs with its unique and diverse proprietary delivery platform to create and develop inhibitory tRNA nanoparticle therapeutics to correct nonsense mutations. ReCode Therapeutics today announced the completion of a $120 million Series B+ Series financing, bringing the total Series B financing to $200 million, with investments from Sanofi Ventures, Amgen Ventures, Leaps by Bayer, and Pfizer.
This article is reproduced from: https://www.itjuzi.com/investevent/13312096
This site is for inclusion only, and the copyright belongs to the original author.